Category: 3. Business

  • Challenging dairy year ahead – Teagasc

    Challenging dairy year ahead – Teagasc

    Weaker milk prices, elevated costs and global market uncertainty mean that Irish dairy farmers are facing into a more challenging year in 2026.

    That’s according to Dr. Emma Dillon, Senior Research Officer and Economist with the Teagasc National Farm Survey who addressed the recent Teagasc Outlook 2026 Conference, and presented a paper co-authored with Trevor Donnellan, Head of the Agricultural Economics and Farm Surveys Department, Teagasc.

    Dr. Dillon highlighted the importance of the global supply and demand context, noting that 2025 marked a year of significant production growth worldwide. Irish milk production is estimated to increase by 4-5% in 2025, EU production up slightly, less than 0.5%, while other key exporting regions such as the US and New Zealand are also expected to publish production increases.

    As a result of this increased supply, Dr. Dillon explained, global dairy commodity markets have been under downward pressure in recent months.

    This volatility fed directly into milk price movements this year. Irish milk prices are estimated to have risen by about 3% year-on-year in 2025, but Dr. Dillon stressed the sector’s reliance on commodity markets: “When those markets are performing well, the Irish milk price will do well. When they are in difficulty, we are in difficulty.”

    Emma Dillon presenting at the Teagasc Outlook Conference

    Dr. Emma Dillon presenting at the Teagasc Outlook 2026 Conference

    Illustrating the impact on this volatility, Dr. Dillon noted that the average dairy farmer is estimated to generate a net margin of 21c/L in 2025 or €2,600/ha, the outlook for 2026 is less positive, however.

    Driven largely by the global trade imbalance, ongoing geopolitical and economic uncertainty, along with oversupplied markets, Dr. Dillon provided a forecast for Irish dairy farms for the year ahead: “We are expecting more moderate supply growth in 2026, with lower prices anticipated in the first half of the year,” Dr. Dillon said. “It is very difficult to pinpoint when prices will recover.”

    For her forecast on margins for the year ahead, Dr. Dillon used an average Irish milk price of 42c/L (actual constituents) or 37c/L (base price), with production expected to remain stable and costs sticking to their elevated levels. Overall, the Teagasc economist forecast that the average dairy farm net margin would fall to €1,500/ha or lower in 2026, with the net margin per litre forecast to dip to 11.5c/L. However, increased returns from calf and cull cow sales are expected to buffer dairy farmers somewhat from lower market prices, especially in the early half of the year.

    Dr. Dillon concluded her presentation by explaining that the Irish dairy sector remains highly exposed to swings in global commodity prices due to the relatively inelastic nature of dairy demand and the slow supply response possible within the sector. However, she noted that the medium to long term prospects look favourable, driven by expected global growth in protein demand and strengthening economic conditions in Southeast Asia, though challenges around inflation and cost of living persist.

    For dairy farmers preparing for the year ahead, Dr. Dillon reinforced the messaging from the recent Teagasc National Dairy Conference on cost control and benchmarking.

    “Dairy farm incomes need to be viewed in the context of almost 1.9 labour units per farm (1.4 labour units being family labour),” Dillon noted. “Benchmarking costs, controlling overheads, stress-testing cash flow and maintaining liquidity will be essential in the year ahead.”

    For full insights and to read Dr. Dillon’s paper from the Teagasc Outlook 2026 Conference, visit here.

    Continue Reading

  • Axed Stagecoach Carlisle bus will leave residents ‘isolated’

    Axed Stagecoach Carlisle bus will leave residents ‘isolated’

    But Wernham said most passengers cannot make the walk to other transport links and asked Cumberland Council and Stagecoach to confirm what assessments were undertaken before the decision was made.

    He has also questioned whether options such as using a smaller single decker bus were considered to keep operating costs down.

    Stagecoach said it had engaged closely with Cumberland Council throughout the review process and will continue to work with the authority to explore any feasible alternatives.

    It comes after the Labour-controlled council launched “Cumberland Go” – a set of subsidised bus services to enhance services operating in and around Carlisle, Anthorn, Whitehaven, Ravenglass, Millom, Barrow and Egremont.

    The BBC has approached Cumberland Council for comment.

    Continue Reading

  • Cadmus Chair uses 3D to bring plumbing code to life

    Cadmus Chair uses 3D to bring plumbing code to life

    Fred Bretzke has amassed about two million views on YouTube for what he describes as “boring” plumbing videos.

    Ten years ago, Bretzke, an instructor in SAIT’s School of Construction, saw an opportunity to inject new life into teaching Plumbing using computer animation. As the 2024/25 Cadmus Trades Teaching Chair, he went a step further — creating a 3D-enhanced supplement to the 2020 National Plumbing Code appendix.

    The Cadmus award is designed to foster faculty excellence in skilled trades teaching. Award recipients receive $20,000 in funding and a four-month break from teaching to work on their project.

    It’s in the code

    As the manual of technical requirements for all plumbing design and installation in Canada, the code book is a critical tool in Bretzke’s teaching toolbox.

    “Parts of the book haven’t changed much over the years,” says Bretzke. “The figures are just stick drawings — many from 40 to 50 years ago. It’s hard to teach from a drawing like that.”

    Securing computer equipment, digital tools and a handful of AI voice programs through his Cadmus budget, Bretzke used his project time (plus some) to create 65 3D animations and eight holograms to help interpret existing code appendix articles from basic installations to detailed plumbing designs.

    After uploading everything to YouTube, he combined screenshots and a QR code link to each animation into a handy reference guide in book form.

    “Each AI-narrated video is about three minutes,” he says. “I did the design, made the animations, wrote the scripts, managed the narrations and put everything together.”

    A screenshot of Bretzke’s 3D code supplement animation for A-2.6.3.1.(2)-A pertaining to potable water systems in commercial kitchens.

    Made for teaching

    The animations are primarily intended as teaching tools for trades instructors.

    “When you’re teaching with the videos, the idea is you stop and start as needed,” he says. “I could probably spend three hours teaching to a three-minute video and explaining all the references.”

    According to Bretzke, a single animation can cover about 15 pages in an apprentice’s Individual Learning Module — the standardized training materials used in trades and technical courses.

    “Trades are very visually oriented,” he says. “Seeing things in 3D helps expedite learning and makes everything more accessible to the student.”

    Bretzke even translated the script for a few of the animations into additional languages, including French, Hindi and Mandarin.

    When he first started using animations in the classroom, some of his students were hesitant, he admits. But if the tech is easy to use, people will use it, he says.

    “I’m teaching my students not to ignore technologies like AI and 3D,” says Bretzke. “I’ve been on construction sites where there’s a 3D artist with no knowledge of the trade working with a plumbing foreman to try and turn a hand drawing into a 3D image. Imagine being a tradesperson who could do both? You’d be a hot commodity.”

    Continue Reading

  • Regulators intervene over Euronext’s plans for ETF settlement

    Regulators intervene over Euronext’s plans for ETF settlement

    French and Dutch regulators have stymied a controversial plan by stock exchange group Euronext that could have driven the settlement of more than 1,250 exchange traded funds to its own platform.

    Euronext unveiled plans earlier this year to consolidate ETF listings on its bourses as a way of improving liquidity. But a related plan that could have made its own central securities depository (CSD) the default settlement venue for Paris and Amsterdam-listed funds triggered an industry backlash over fears of higher costs. Rival Euroclear and market maker Jane Street were among those critical of the plan.

    However, intervention by regulators the Autorité des Marchés Financiers and the Autoriteit Financiële Markten has pushed Euronext to change its plans.

    “The regulators took a view and we are now adjusting that,” said Pierre Davoust, head of Euronext’s depository Euronext Securities. He added that regulators “have asked us to review” the connectivity between it and Euroclear — a move that maintains a choice of settlement venue for traders.

    “We never intended to discriminate against any CSD,” he said. “The purpose of the project was never to deny customers the choice. It was to give them choice.”

    Euroclear said in a statement that, as a result of complaints it had made, the AMF and the AFM judged Euronext’s plans to be “discriminatory . . . not justified by a risk which may affect the smooth and orderly functioning of the financial markets . . .[and] not justified by the necessity to ensure the efficient and economic settlement of the transactions”.

    The AMF declined to comment. The AFM said it could not comment on specific cases, but added: “In general, the AFM aims to ensure fair competition between CSDs. Open access, where market participants such as exchanges, central counterparties and CSDs grant access to each other’s infrastructures, contributes to this goal.” 

    The intervention by regulators has been greeted positively by many in the industry.

    “Our members welcome recent developments that will grant them the flexibility to continue to settle through the ICSD [international central securities depository],” said Lara Shevchenko, markets structure expert at the European Principal Traders Association, an industry body representing 20 market makers.

    “This will ensure current levels of settlement efficiency in European ETF markets are maintained,” she added.

    Jim Goldie, Emea head of capital markets, ETFs and indexed strategies at Invesco, said keeping a choice of depositories “is a good outcome for investors”.

    The plan by Euronext — which operates seven stock exchanges across Europe, including Milan, Paris and Amsterdam — to consolidate ETF listings was broadly welcomed by the industry, as it was seen to be tackling the fragmentation and illiquidity that often stems from a single ETF being listed on several exchanges.

    But many in the sector had feared the related proposal to make Euronext Securities, where its Milan ETFs are already settled, the default settlement venue for ETFs listed in Paris and Amsterdam would mean a rise in post-trade fragmentation.

    At present, most European ETF trades are settled on international CSDs operated by Euroclear and Clearstream, which has the effect of unifying trade settlement.

    One issue with the Euronext plan was the fact that many of the ETFs listed in France and the Netherlands are also cross-listed on other European bourses, such as the London, Swiss and Xetra exchanges, where market participants settle through ICSDs.

    Even for Euronext’s own listings, its settlement plans would have only applied to the quarter of ETF trading conducted on exchange, with other trades still settled via ICSDs.

    Moreover, Euronext Securities only supports euro-denominated ETFs, meaning a trader wanting to switch between dollar and euro share classes would need to settle in two different locations. It also only covers secondary market trades, with primary market activity — the creation and redemption of ETF shares — still settled via Euroclear.

    The fear was that this fragmentation would have split inventories, meaning more switching of stocks between venues would be necessary. This would have raised costs and increased the risk of settlement “fails”, which market makers would be penalised for.

    The cost of paying these penalties would likely be recouped by market makers quoting wider bid-offer spreads, which would disadvantage end investors.

    Jane Street put out research earlier this year saying that Euronext’s proposed changes may “make timely settlement more operationally challenging”.

    It added: “This could have a knock-on effect on spreads in ETFs as market makers incorporate potentially higher operational costs and penalties from late settlement into their prices.”

    As a result of Euronext’s changes to its plans following discussions with the regulator, it will still name its own depository as the default for Paris and Amsterdam-listed ETFs from September 2026, but will make it easier for market participants to opt out and use an alternative venue.

    “Trading members will be able to continue using the Euroclear CSD,” said Euronext’s Davoust. “We want to provide competition and choice and give our clients the option to settle outside of Euroclear. There are retail brokers who would prefer that.”

    Continue Reading

  • How Amazon is supporting impacted communities in Washington state

    How Amazon is supporting impacted communities in Washington state

    “Amazon has stepped up when disasters strike since 2017, contributing more than 26 million in emergency supplies and technology in response to more than 200 disasters around the world. This time, a disaster is impacting communities in our home state of Washington, and we’re committed to being the best employer and neighbor that we can be and mobilizing our strengths in volunteering, logistics, and speed to support our teammates and neighbors,” said Amazon’s Head of Community Impact Bettina Stix.

    Continue Reading

  • Government-formed agency recommends against NSW coal industry expansion

    Government-formed agency recommends against NSW coal industry expansion

    Coal mining extensions and expansions will continue, the New South Wales premier says, despite a government-appointed agency finding further approvals would be inconsistent with emissions targets.

    The Net Zero Commission was set up in 2023 to advise the state government on progress towards its legislated goals, including a 50 per cent reduction by 2030 and net-zero emissions by 2050.

    In a report released on Friday, the agency found extensions or expansions to coal mining in the state were neither consistent with those targets nor the Paris Agreement to limit global warming.

    The Net Zero Commission report found expansions to coal mining were inconsistent with NSW’s emissions goals. (ABC News: Michael Barnett)

    But Premier Chris Minns on Saturday said it would be “irresponsible” to stop project approvals with immediate effect.

    “We’re not going to make that ruling, and I’m not going to make that promise,” he said.

    “I’ve said from the very beginning … mining, particularly in the Hunter [region], is still important for the New South Wales economy, it’s our single biggest export.

    nsw premier chris minns talks to the  media outdoors in newcastle

    Chris MInns says it would be “irresponsible” to stop coal mining project approvals in NSW.  (ABC News)

    “Yes, our trading partners are getting out of it. Yes the people that buy that coal will buy less of it in the years ahead.

    “At the same time as we are running a million miles an hour to bring on renewable energy in New South Wales, we are trying to manage this transition in the economy as best as we can, and that’s just not consistent with shutting it down overnight.”

    Industry critical of report

    The NSW Minerals Council, which represents the state’s coal mining industry, said the commission’s report was a “flawed and superficial analysis” that risked thousands of mining jobs.

    NSW has 37 operating coal mines, according to the Net Zero Commission report, with 17 expansion or extension projects in the planning pipeline, which the agency warned would significantly increase emissions if approved.

    The commission found the existing process for determining the approval of mine extensions failed to robustly address emissions implications.

    A hill with a coal mine cut out of the side

    BHP’s Mt Arthur site is one of 37 operating coal mines in NSW. (ABC Upper Hunter: Jake Lapham)

    It recommended consent authorities be required to consider the impact of indirect emissions, called “scope 3” emissions, which are beyond the company’s control.

    The report found the vast majority of emissions associated with NSW coal mines were generated overseas as 87 per cent of the state’s coal was exported.

    NSW Minerals Council CEO Stephen Galilee said the state’s coal mining industry had cut emissions faster than any other sector.

    Stephen Galilee

    Stephen Galilee says coal mining contributes about 12 per cent of the state’s total emissions. (Supplied)

    “Coal mining contributes around 12 per cent of the state’s total emissions,” Mr Galilee said in a statement.

    “That means around 88 per cent of New South Wales emissions are generated by sectors other than coal mining.

    “If the Net Zero Commission was truly ‘independent’ it would focus on emissions across the wider economy.”

    ‘Very serious moment’

    Nic Clyde from activist group Lock the Gate said the report was believed to be the first instance of a government agency in Australia calling for an end to the expansion of coal mining.

    “It’s a very serious moment. It’s a real rock in the pond for climate politics in NSW,” Mr Clyde said.

    “It really does require an urgent response from the government.”

    Continue Reading

  • News Releases from Department of Health

    News Releases from Department of Health

    DOH ALERTS PUBLIC ABOUT MEDINATURA NEW MEXICO’S REBOOST NASAL SPRAY DUE TO POTENTIAL YEAST/MOLD AND MICROBIAL CONTAMINATION

    Posted on Dec 12, 2025 in Newsroom

    HONOLULU — The Hawai‘i Department of Health (DOH) Food and Drug Branch (FDB) is alerting residents to a recall issued by MediNatura New Mexico, Inc. for its ReBoost Nasal Spray. The recall was issued because of potential yeast/mold and microbial contamination, with one species identified as Achromobacter, at levels above specifications.

    The recalled product was distributed nationwide, including retailers like Foodland in Hawai‘i, as well as direct-to-consumer via internet sales (medinatura.com). FDB is working with the local stores to ensure that the recalled product is no longer available for sale. The recalled product information is as follows: 

    Product NDC UPC Lot Expiration
    ReBoost Nasal Spray 20 mL 62795-4005-9 7 87647 10186 3 224268 12/2027  

    Microbial contamination in nasal spray may lead to adverse health consequences, including life-threatening effects in immunocompromised individuals who use the product. Symptoms may include fever, swollen sinuses, headaches, face pain or pressure and facial numbness. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. To date, there have been no reports of adverse events related to this recall.

    The FDB advises consumers to verify that they possess the recalled product and stop using it immediately. Customers who purchased the product directly from MediNatura New Mexico, Inc. may request a refund by emailing [email protected]. Consumers who purchased it at a local store may return it to the place of purchase.

    Consumers with questions regarding this recall may contact MediNatura New Mexico, Inc. at 800-621-7644 Monday through Friday from 5 a.m. to 2 p.m. HST, or by email at [email protected].

    Representative images of the recalled product are displayed below: 

    # # #

    Continue Reading

  • Guo, Y. Wang Yong-qing. Confusion in diagnosis and treatment of cervical insufficiency[J]. Int. Reprod. Health/Fam Plan. 37 (05), 417–421 (2018).

    Google Scholar 

  • DaCosta, V. et al. Laparoscopic cervicoisthmic cerclage for the treatment of cervical incompetence: case reports. West. Indian Med. J. 60 (5), 590–593 (2011).

    Google Scholar 

  • Brown, R., Gagnon, R. & Delisle, M. F. 373-Cervical insufficiency and cervical cerclage. J. Obstet. Gynaecol. Can. 41 (2), 233–247 (2019).

    Google Scholar 

  • Goldenberg, R. L., Culhane, J. F., Iams, J. D. & Romero, R. Epidemiology and causes of preterm birth. Lancet 371 (9606), 75–84 (2008).

    Google Scholar 

  • Roman, A., Suhag, A. & Berghella, V. Overview of cervical insufficiency: diagnosis, etiologies, and risk factors. Clin. Obstet. Gynecol. 59, 23–40 (2016).

    Google Scholar 

  • Han, Y., Li, M., Ma, H. & Yang, H. Cervical insufficiency: a noteworthy disease with controversies. J. Perinat. Med. 48 (7), 648–655 (2020).

    Google Scholar 

  • Gascón, A. et al. Cervical cerclage vs cervical Pessary in women with cervical insufficiency: A multicentric, open-label, randomised, controlled pilot trial [the CEPEIC trial]. Eur. J. Obstet. Gynecol. Reprod. Biol. X. 24, 100347 (2024).

    Google Scholar 

  • Zhu, L. Q. et al. Effects of emergency cervical cerclage on pregnancy outcome: a retrospective study of 158 cases. Med. Sci. Monit. 21, 1395–1401 (2015).

    Google Scholar 

  • Chen, Q., Chen, G. & Li, N. Clinical effect of emergency cervical cerclage and elective cervical cerclage on pregnancy outcome in the cervical-incompetent pregnant women. Arch. Gynecol. Obstet. 297 (2), 401–407 (2018).

    Google Scholar 

  • Wang, Y., Gu, X., Tao, L. & Zhao, Y. Co-morbidity of cervical incompetence with polycystic ovarian syndrome (PCOS) negatively impacts prognosis: A retrospective analysis of 178 patients. BMC Pregnancy Childbirth. 16 (1), 308 (2016).

    Google Scholar 

  • Feigenbaum, S. L. et al. Prevalence of cervical insufficiency in polycystic ovarian syndrome. Hum. Reprod. 27 (9), 2837–2842 (2012).

    Google Scholar 

  • Meng, L., Öberg, S., Sandström, A., Wang, C. & Reilly, M. Identification of risk factors for incident cervical insufficiency in nulliparous and Parous women: a population-based case-control study. BMC Med. 20 (1), 348 (2022).

    Google Scholar 

  • Anum, E. A., Hill, L. D., Pandya, A. & Strauss, J. F. 3rd Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity. Placenta 30 (3), 207–215 (2009).

    Google Scholar 

  • Spiegel, E., Nicholls-Dempsey, L., Czuzoj-Shulman, N. & Abenhaim, H. A. Pregnancy outcomes in women with Ehlers-Danlos syndrome. J. Matern Fetal Neonatal Med. 35 (9), 1683–1689 (2022).

    Google Scholar 

  • Richard, D. et al. Calculating the sample size required for developing a clinical prediction model. BMJ 368, m441 (2020).

    Google Scholar 

  • Meng, L., Öberg, S., Sandström, A. & Reilly, M. Association between infertility and cervical insufficiency in nulliparous women- the contribution of fertility treatment. Am. J. Obstet. Gynecol. 28, S0002-9378(24)01107-4.

  • Wu, Y. et al. Development and validation of a model for individualized prediction of cervical insufficiency risks in patients undergoing IVF/ICSI treatment. Reprod. Biol. Endocrinol. 19 (1), 6 (2021).

    Google Scholar 

  • Sun, X. et al. Independent value of PMOI on hCG day in predicting pregnancy outcomes in IVF/ICSI cycles. Front. Endocrinol. (Lausanne). 14, 1086998 (2023).

    Google Scholar 

  • Liu, B. et al. Association between maternal pre-pregnancy obesity and preterm birth according to maternal age and race or ethnicity: a population-based study. Lancet Diabetes Endocrinol. 7 (9), 707–714 (2019).

    Google Scholar 

  • Shetelig Løvvik, T., Stridsklev, S., Carlsen, S. M., Salvesen, Ø. & Vanky, E. Cervical length and androgens in pregnant women with polycystic ovary syndrome: has Metformin any effect? J. Clin. Endocrinol. Metab. 101 (6), 2325–2331 (2016).

    Google Scholar 

  • Makieva, S., Saunders, P. T. & Norman, J. E. Androgens in pregnancy: roles in parturition[J]. Hum. Reprod. Update. 20 (4), 542–559 (2014).

    Google Scholar 

  • Sundtoft, I., Langhoff-Roos, J., Sandager, P., Sommer, S. & Uldbjerg, N. Cervical collagen is reduced in non-pregnant women with a history of cervical insufficiency and a short cervix. Acta Obstet. Gynecol. Scand. 96 (8), 984–990 (2017).

    Google Scholar 

  • Timmons, B., Akins, M. & Mahendroo, M. Cervical remodeling during pregnancy and parturition. Trends Endocrinol. Metab. 21 (6), 353–361 (2010).

    Google Scholar 

  • Biffignandi, P., Massucchetti, C. & Molinatti, G. M. Female hirsutism: pathophysiological considerations and therapeutic implications. Endocr. Rev. 5 (4), 498–513 (1984).

    Google Scholar 

  • Wu Jing, L. & Ruojia, C. Significance of different androgen indexes in the diagnosis of hyperandrogenemia in polycystic ovary syndrome. Zhejiang Med. J. 43 (5), 537–539 (2021).

    Google Scholar 

  • Pankhurst, M. W. A putative role for anti-Mullerian hormone (AMH) in optimising ovarian reserve expenditure. J. Endocrinol. 233 (1), R1–R13 (2017).

    Google Scholar 

  • Sun, X. et al. Comparison of the predictive capability of antral follicle count vs. the anti-Müllerian hormone for ovarian response in infertile women. Front. Endocrinol. (Lausanne). 13, 862733 (2022).

    Google Scholar 

  • Sun, X. Y. et al. Relationship between Anti-Müllerian hormone and in vitro Fertilization-Embryo transfer in clinical pregnancy. Front. Endocrinol. (Lausanne). 11, 595448 (2020).

    Google Scholar 

  • Hu, K. L., Liu, F. T., Xu, H., Li, R. & Qiao, J. High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome. Fertil. Steril. 113 (2), 444–452e1 (2020).

    Google Scholar 

  • Hsu, J. Y. et al. Mullerian-Inhibiting Substance/Anti-Mullerian hormone as a predictor of preterm birth in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 103 (11), 4187–4196 (2018).

    Google Scholar 

  • Kaing, A. et al. Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction. Fertil. Steril. 115 (2), 438–446 (2021).

    Google Scholar 

  • Kang, J. Molecular Mechaisms of Mouse Mullerian Duct development[D] (Beijing, Beijing Xiehe Medical College Hospital, Chinese Academy of Medical Sciences,, 2020).

  • Song, J. Y. et al. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer. Int. J. Oncol. 40 (6), 2013–2021 (2012).

    Google Scholar 

  • Wei, Y. et al. Preconception diabetes mellitus and adverse pregnancy outcomes in over 6.4 million women: A population-based cohort study in China. PLoS Med. 16 (10), e1002926 (2019).

    Google Scholar 

  • Michalik, L. & Wahli, W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Invest. 116 (3), 598–606 (2006).

    Google Scholar 

  • Werner, S. & Grose, R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83 (3), 835–870 (2003).

    Google Scholar 

  • Khamaisi, M. et al. PKCδ Inhibition normalizes the wound-healing capacity of diabetic human fibroblasts. J. Clin. Invest. 126 (3), 837–853 (2016).

    Google Scholar 

  • Li, R. et al. Prevalence of polycystic ovary syndrome in women in china: A large Community-Based study. Hum. Reprod. 28 (9), 2562–2569 (2013).

    Google Scholar 

  • Hawkins, L. K., Correia, K. F., Srouji, S. S., Hornstein, M. D. & Missmer, S. A. Uterine length and fertility outcomes: a cohort study in the IVF population. Hum. Reprod. 28 (11), 3000–3006 (2013).

    Google Scholar 

  • Gökçe, A. et al. The association between operative hysteroscopy prior to assisted reproductive technology and cervical insufficiency in second trimester. Arch. Gynecol. Obstet. 303 (5), 1347–1352 (2021).

    Google Scholar 

  • Shi, Y. et al. Transfer of fresh versus frozen embryos in ovulatory women. N Engl. J. Med. 378 (2), 126–136 (2018).

    Google Scholar 

  • Liu, Y., Li, R. & Wang, Y. Clinical outcomes and placental pathological characteristics after fresh embryo transfer and frozen-thawed embryo transfer with different endometrial Preparation protocols. Placenta 131, 65–70 (2023).

    Google Scholar 

Continue Reading

  • U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

    HORSHAM, PA, December 12, 2025/PRNewswire/ – Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by previously available therapies.2

    “There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the mutation,” said Bradley McGregor, M.D., Director of Clinical Research for the Lank Center of Genitourinary Oncology at Dana-Farber Cancer Institute. “AMPLITUDE is the first study to show that this precision medicine combination of a PARP inhibitor with an androgen receptor pathway inhibitor delays both radiographic and symptomatic disease progression.”

    The approval is based on positive results from AMPLITUDE (NCT04497844), a randomized, double-blind, placebo-controlled, international Phase 3 clinical study. In patients with BRCA2-mutated mCSPC, treatment with AKEEGA® plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54 percent (hazard ratio [HR] 0.46; 95 percent confidence interval [CI], 0.32–0.66) compared to placebo/abiraterone acetate plus prednisone and ADT, which is the current standard of care.1 AKEEGA® plus prednisone and ADT also significantly prolonged the time to symptomatic progression by 59 percent (HR 0.41; 95 percent CI, 0.29–0.65).1

    The observed safety profile of the combination of AKEEGA® plus prednisone was consistent with the known safety profile of each FDA-approved monotherapy. In the AMPLITUDE clinical study, the most common adverse reactions (≥20%) including laboratory abnormalities, were decreased hemoglobin, decreased lymphocytes, musculoskeletal pain, fatigue, decreased platelets, increased alkaline phosphatase, constipation, hypertension, nausea, decreased neutrophils, increased creatinine, increased potassium, decreased potassium, decreased aspartate aminotransferase, fluid retention/edema, increased bilirubin, respiratory tract infection and arrhythmia.1

    “This expanded indication for AKEEGA reflects our commitment to push the boundaries of science and deliver more personalized, effective treatment options across the prostate cancer continuum,” said Mahadi Baig, M.D., M.H.C.M., Vice President, Head of Solid Tumors, U.S. Medical Affairs, Johnson & Johnson Innovative Medicine. “Supported by strong clinical data, AKEEGA is now the first and only PARP-based precision medicine combination treatment in BRCA2-mutated mCSPC, offering patients hope for more time with a new way to potentially delay their cancer from progressing.”

    Johnson & Johnson is committed to helping patients access our treatments. Once a patient and their doctor have decided that AKEEGA® is right for the patient, J&J withMe provides a simple, comprehensive patient support program offering cost support and educational resources, at no cost to the patient.

    *The hazard ratio [HR] 0.46; 95 percent confidence interval [CI], 0.32–0.66) compared to standard of care, AKEEGA® plus prednisone and ADT also significantly prolonged the time to symptomatic progression by 59 percent (HR 0.41; 95 percent CI, 0.29–0.65).1

    About AMPLITUDE
    AMPLITUDE (NCT04497844) is an ongoing, Phase 3, randomized, double-blind, placebo-controlled, multicenter, global study evaluating the efficacy and safety of niraparib and abiraterone acetate in a dual-action tablet (DAT) formulation with prednisone plus androgen deprivation therapy (ADT) compared to matching oral placebo/abiraterone acetate with prednisone plus ADT in patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). The primary endpoint is radiographic progression-free survival (rPFS). The study enrolled 696 participants from 32 countries.

    About Metastatic Castration-Sensitive Prostate Cancer
    Metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC), refers to prostate cancer that has spread to other parts of the body but still responds to hormone therapy (androgen deprivation therapy).3 While the treatment landscape has advanced in recent years, almost all patients eventually develop resistance to therapy, and the disease progresses to metastatic castration-resistant prostate cancer (mCRPC) – an aggressive and currently incurable disease stage.4 Approximately 25 percent of patients with mCSPC have HRR gene alterations, including BRCA, which have been shown to negatively impact outcomes.2,5 Patients with BRCA mutations experience approximately 50 percent faster disease progression and shorter survival, representing a significant unmet medical need not addressed by previously available therapies.2

    About AKEEGA® (niraparib and abiraterone acetate)
    AKEEGA® is a dual-action tablet (DAT), combining niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor. AKEEGA® together with prednisone or prednisolone was approved in April 2023 by the European Medicines Agency, and in August 2023 by the U.S. FDA following Priority Review, for the treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). AKEEGA® plus prednisone was approved by the U.S. FDA in December 2025 under Priority Review for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Patients are selected for therapy based on an FDA-approved test for genetic alterations. Additional marketing authorization applications are under review across a number of countries globally.

    In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GlaxoSmithKline [GSK] in 2019) for exclusive rights to niraparib in prostate cancer.

    For more information visit www.akeegahcp.com.

    AKEEGA® INDICATIONS AND IMPORTANT SAFETY INFORMATION

    INDICATIONS

    AKEEGA® is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with:

    • deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC).
    • deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
    • Select patients for therapy based on an FDA approved test for AKEEGA®

    IMPORTANT SAFETY INFORMATION

    WARNINGS AND PRECAUTIONS

    Myelodysplastic Syndrome/Acute Myeloid Leukemia
    AKEEGA® may cause myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).

    In the individual AMPLITUDE and MAGNITUDE studies, MDS or AML, including cases with fatal outcomes, were reported in 0.6% (2/347) and 0.5% (1/212) of patients treated with AKEEGA® plus prednisone, respectively.

    All patients in other tumor types treated with niraparib, a component of AKEEGA®, who developed secondary MDS/cancer-therapy-related AML had received previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.

    For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation. Discontinue AKEEGA® if MDS/AML is confirmed.

    Myelosuppression
    AKEEGA® may cause myelosuppression (anemia, thrombocytopenia, or neutropenia).

    In AMPLITUDE, Grade 3-4 anemia, neutropenia, and thrombocytopenia were reported, respectively in 29 %, 10 %, and 4.9% of patients receiving AKEEGA®. Overall, 25% of patients with anemia required a red blood cell transfusion, including 15% who required more than one transfusion. Discontinuation due to anemia occurred in 1.2% of patients.

    In MAGNITUDE Cohort 1, Grade 3-4 anemia, thrombocytopenia, and neutropenia were reported, respectively in 28%, 8%, and 7% of patients receiving AKEEGA®. Overall, 27% of patients with anemia required a red blood cell transfusion, including 19.5% who required more than one transfusion. Discontinuation due to anemia occurred in 3% of patients.

    Monitor complete blood counts weekly during the first month of AKEEGA® treatment, every two weeks for the next two months, monthly for the remainder of the first year and then every other month, and as clinically indicated. Do not start AKEEGA® until patients have adequately recovered from hematologic toxicity caused by previous therapy. If hematologic toxicities do not resolve within 28 days following interruption, discontinue AKEEGA® and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.

    Hypokalemia, Fluid Retention, and Cardiovascular Adverse Reactions
    AKEEGA® may cause hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. In post-marketing experience, QT prolongation and Torsades de Pointes have been observed in patients who develop hypokalemia while taking abiraterone acetate, a component of AKEEGA®.Hypertension and hypertensive crisis have also been reported in patients treated with niraparib, a component of AKEEGA®.

    In AMPLITUDE, which used prednisone 5 mg daily in combination with AKEEGA®, Grades 3-4 hypokalemia was detected in 9% of patients on the AKEEGA® arm, and Grades 3-4 hypertension was observed in 30% of patients on the AKEEGA® arm.

    In MAGNITUDE Cohort 1, which used prednisone 10 mg daily in combination with AKEEGA®, Grades 3-4 hypokalemia was detected in 2.7% of patients on the AKEEGA® arm and Grades 3-4 hypertension was observed in 14% of patients on the AKEEGA® arm.

    Monitor patients for hypertension, hypokalemia, and fluid retention at least weekly for the first two months, then once a month. Closely monitor patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia, or fluid retention, such as those with heart failure, recent myocardial infarction, cardiovascular disease, or ventricular arrhythmia. Control hypertension and correct hypokalemia before and during treatment with AKEEGA®. Discontinue AKEEGA® in patients who develop hypertensive crisis or other severe cardiovascular adverse reactions.

    The safety of AKEEGA® in patients with New York Heart Association (NYHA) Class II to IV heart failure has not been established because these patients were excluded from AMPLITUDE and MAGNITUDE.

    Hepatotoxicity
    AKEEGA® may cause hepatotoxicity.

    Hepatotoxicity in patients receiving abiraterone acetate, a component of AKEEGA®, has been reported in clinical trials. In post-marketing experience, there have been abiraterone acetate-associated severe hepatic toxicity, including fulminant hepatitis, acute liver failure, and deaths.

    In AMPLITUDE, Grade 3-4 ALT or AST increases (at least 5x ULN) were reported in 1.9% and 1.3% of patients, respectively.

    In MAGNITUDE Cohort 1, Grade 3-4 ALT or AST increases (at least 5x ULN) were reported in 1.8% and 0.9% of patients respectively.

    The safety of AKEEGA in patients with moderate or severe hepatic impairment has not been established as these patients were excluded from AMPLITUDE and MAGNITUDE.

    Measure serum transaminases (ALT and AST) and bilirubin levels prior to starting treatment with AKEEGA®, every two weeks for the first three months of treatment and monthly thereafter. Promptly measure serum total bilirubin, AST, and ALT if clinical symptoms or signs suggestive of hepatotoxicity develop.Elevations of AST, ALT, or bilirubin from the patient’s baseline should prompt more frequent monitoring and may require dosage modifications.

    Permanently discontinue AKEEGA® for patients who develop a concurrent elevation of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation, or in patients who develop ALT or AST ≥20 x ULN at any time after receiving AKEEGA®.

    Adrenocortical Insufficiency
    AKEEGA® may cause adrenal insufficiency.

    Adrenocortical insufficiency has been reported in clinical trials in patients receiving abiraterone acetate, a component of AKEEGA®, in combination with prednisone, following interruption of daily steroids and/or with concurrent infection or stress. Monitor patients for symptoms and signs of adrenocortical insufficiency, particularly if patients are withdrawn from prednisone, have prednisone dose reductions, or experience unusual stress. Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with abiraterone acetate. If clinically indicated, perform appropriate tests to confirm the diagnosis of adrenocortical insufficiency. Increased doses of corticosteroids may be indicated before, during, and after stressful situations.

    Hypoglycemia
    AKEEGA® may cause hypoglycemia in patients being treated with other medications for diabetes.

    Severe hypoglycemia has been reported when abiraterone acetate, a component of AKEEGA®, was administered to patients receiving medications containing thiazolidinediones (including pioglitazone) or repaglinide.

    Monitor blood glucose in patients with diabetes during and after discontinuation of treatment with AKEEGA®. Assess if antidiabetic drug dosage needs to be adjusted to minimize the risk of hypoglycemia.

    Increased Fractures and Mortality in Combination with Radium 223 Dichloride
    AKEEGA® with prednisone is not recommended for use in combination with Ra-223 dichloride outside of clinical trials.

    The clinical efficacy and safety of concurrent initiation of abiraterone acetate plus prednisone/prednisolone and radium Ra 223 dichloride was assessed in a randomized, placebo-controlled multicenter study (ERA-223 trial) in 806 patients with asymptomatic or mildly symptomatic castration-resistant prostate cancer with bone metastases. The study was unblinded early based on an Independent Data Monitoring Committee recommendation.

    At the primary analysis, increased incidences of fractures (29% vs 11%) and deaths (39% vs 36%) have been observed in patients who received abiraterone acetate plus prednisone/prednisolone in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus prednisone.

    It is recommended that subsequent treatment with Ra-223 not be initiated for at least five days after the last administration of AKEEGA®, in combination with prednisone.

    Posterior Reversible Encephalopathy Syndrome
    AKEEGA® may cause Posterior Reversible Encephalopathy Syndrome (PRES).
    PRES has been observed in patients treated with niraparib as a single agent at higher than the recommended dose of niraparib included in AKEEGA®.

    Monitor all patients treated with AKEEGA® for signs and symptoms of PRES. If PRES is suspected, promptly discontinue AKEEGA® and administer appropriate treatment. The safety of reinitiating AKEEGA® in patients previously experiencing PRES is not known.

    Embryo-Fetal Toxicity
    The safety and efficacy of AKEEGA® have not been established in females. Based on animal reproductive studies and mechanism of action, AKEEGA® can cause fetal harm and loss of pregnancy when administered to a pregnant female.

    Niraparib has the potential to cause teratogenicity and/or embryo-fetal death since niraparib is genotoxic and targets actively dividing cells in animals and patients (e.g., bone marrow).

    In animal reproduction studies, oral administration of abiraterone acetate to pregnant rats during organogenesis caused adverse developmental effects at maternal exposures approximately ≥ 0.03 times the human exposure (AUC) at the recommended dose.

    Advise males with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of AKEEGA®. Females who are or may become pregnant should handle AKEEGA® with protection, e.g., gloves.

    ADVERSE REACTIONS
    BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
    Serious adverse reactions occurred in 36% of patients who received AKEEGA®. Serious adverse reactions reported in >2% of patients included anemia (4.9%), and pneumonia (3.7%). Fatal adverse reactions occurred in 4.9% of patients who received AKEEGA®, including sudden death (1. 9%), COVID-19 pneumonia (1.2%), pneumocystis jirovecii pneumonia (0.6%), pneumonia (0.6%), and cardio-respiratory arrest (0.6%).

    The most common adverse reactions (>20%), including laboratory abnormalities, in patients who received AKEEGA® were decreased hemoglobin, decreased lymphocyte count, hypertension, decreased neutrophil count, musculoskeletal pain, decreased platelet count, constipation, fatigue, decreased potassium, increase creatinine, nausea, increased alkaline phosphate, increased aspartate aminotransferase, respiratory tract infection, arrhythmia, increased blood bilirubin, and fluid retention/edema.

    BRCA-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Serious adverse reactions occurred in 41% of patients who received AKEEGA®. Serious adverse reactions reported in >2% of patients included COVID-19 (7%), anemia (4.4%), pneumonia (3.5%), and hemorrhage (3.5%). Fatal adverse reactions occurred in 9% of patients who received AKEEGA®, including COVID-19 (5%), cardiopulmonary arrest (1%), dyspnea (1%), pneumonia (1%), and septic shock (1%).

    The most common adverse reactions (>20%), including laboratory abnormalities, in patients who received AKEEGA® were hemoglobin decreased, lymphocyte decreased, musculoskeletal pain, fatigue, platelets decreased, constipation, alkaline phosphatase increased, hypertension, nausea, neutrophils decreased, creatinine increased, potassium increased, potassium decreased, and aspartate aminotransferase increased.

    DRUG INTERACTIONS

    Effect of Other Drugs on AKEEGA®
    Avoid coadministration with strong CYP3A4 inducers.
    Abiraterone is a substrate of CYP3A4. Strong CYP3A4 inducers may decrease abiraterone concentrations, which may reduce the effectiveness of abiraterone.

    Effects of AKEEGA® on Other Drugs
    CYP2D6 Substrates
    Avoid coadministration unless otherwise recommended in the Prescribing Information for CYP2D6 substrates for which minimal changes in concentration may lead to serious toxicities. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug.

    Abiraterone is a CYP2D6 moderate inhibitor. AKEEGA® increases the concentration of CYP2D6 substrates, which may increase the risk of adverse reactions related to these substrates.

    CYP2C8 Substrates
    Monitor patients for signs of toxicity related to a CYP2C8 substrate for which a minimal change in plasma concentration may lead to serious or life-threatening adverse reactions.

    Abiraterone is a CYP2C8 inhibitor. AKEEGA® increases the concentration of CYP2C8 substrates, which may increase the risk of adverse reactions related to these substrates.

    USE IN SPECIFIC POPULATIONS

    Geriatric Use

    Of the 162 patients with BRCA2 gene alteration(s) who received AKEEGA® in AMPLITUDE, 40% of patients were less than 65 years, 36% of patients were 65 years to 74 years, and 23% were 75 years and over.

    Of the 113 patients with BRCA gene alteration(s) who received AKEEGA® in MAGNITUDE, 34.5% of patients were less than 65 years, 38.9% of patients were 65 years to 74 years, and 26.5% were 75 years and over.

    No overall differences in effectiveness were observed between patients 65 years of age or older and younger patients in AMPLITUDE or MAGNITUDE. Patients 75 years of age or older who received AKEEGA® experienced a higher incidence of fatal adverse reactions than younger patients. The incidence of fatal adverse reactions was 4.3% in patients younger than 75 and 13% in patients 75 or older.

    Hepatic Impairment

    Avoid use in patients with moderate or severe hepatic impairment. No dosage modification is necessary for patients with mild hepatic impairment.

    Renal Impairment

    Monitor patients with severe renal impairment for increased adverse reactions and modify dosage as recommended for adverse reactions. No dosage modification is recommended for patients with mild to moderate renal impairment.

    Please see the full Prescribing Information for AKEEGA®.

    About Johnson & Johnson
    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies.

    Cautions Concerning Forward-Looking Statements
    This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of AKEEGA®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    Footnotes
    1 AKEEGA® U.S. Prescribing Information.

    2 Olmos D, Lorente D, Jambrina A, et al. BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 2025;36(10):1190-1202. doi:10.1016/j.annonc.2025.05.534

    3 National Cancer Institute. Hormone-sensitive prostate cancer. Accessed December 2025. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hormone-sensitive-prostate-cancer

    4 Narayan V, et al. Treatment patterns and survival outcomes among androgen receptor pathway inhibitor-experienced patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2024;22(6):1-14. doi:10.1016/j.clgc.2024.102188

    5 Gonzalez D, Mateo J, Stenzinger A, et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J Pathol Clin Res. 2021;7(4):311-325. doi:10.1002/cjp2.203


    Continue Reading

  • Corebridge Financial Set to Join S&P MidCap 400

    NEW YORK, Dec. 12, 2025 /PRNewswire/ — Corebridge Financial Inc. (NYSE: CRBG) will replace Allete Inc. (NYSE: ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions.

    Following is a summary of the change that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name

    Action

    Company Name

    Ticker

    GICS Sector

    Dec 17, 2025

    S&P MidCap 400

    Addition

    Corebridge Financial

    CRBG

    Financials

    Dec 17, 2025

    S&P MidCap 400

    Deletion

    Allete

    ALE

    Utilities

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

    FOR MORE INFORMATION:

    S&P Dow Jones Indices
    index_services@spglobal.com

    Media Inquiries
    spdji.comms@spglobal.com

    SOURCE S&P Dow Jones Indices

    Continue Reading